Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle

• Published in: European journal of pediatrics Vol. 177; no. 6; pp. 891 - 902
• Main Authors: Tsimicalis, Argerie, Boitor, Madalina, Ferland, Catherine E., Rauch, Frank, Le May, Sylvie, Carrier, Jaimie Isabel, Ngheim, Tracy, Bilodeau, Claudette
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-06-2018; Springer Nature B.V
• Subjects: Adolescents; Bisphosphonates; Children; Children & youth; Chronic pain; Intravenous administration; Medicine; Medicine & Public Health; Original Article; Osteogenesis; Osteogenesis imperfecta; Pain; Pediatrics; Quality of life; Teenagers; Zoledronic acid; Osteogenesis imperfecta; Pediatrics; Pain; Bisphosphonate treatment; Quality of life
• ISSN: 0340-6199; 1432-1076
• DOI: 10.1007/s00431-018-3127-9

The objective was to describe the pain and quality of life among children and adolescents with any osteogenesis imperfecta (OI) type over one intravenous bisphosphonate treatment cycle from a child and parental perspective. A prospective, observational study was conducted, where children and adolescents evaluated their pain intensity, location, and quality, as well as quality of life before, 1 week after treatment, and 6 months later. Quality of life was also evaluated from the parental perspective at the same three time points. Thirty-three child/parent dyads participated. The results showed that pain intensity on the 0–10 self-report scale after the Zoledronate infusion (median = 0, range = 0–6) was not different from pre (median = 2, range = 0–10) and 6-months post-scores (median = 2, range = 0–8) (
p
 = 0.170). Children and adolescents with OI reported experiencing pain mainly in the ankles and the anterior and posterior shoulders. They selected evaluative pain descriptors such as uncomfortable (
n
 = 16, 48%) and annoying (
n
 = 13, 39%). Children and adolescents’ functioning and quality of life did not change significantly across the bisphosphonate treatment cycle (
p
 = 0.326), parents perceived an improvement immediately after the treatment compared to before (
p
 = 0.016).
Conclusion
: Children and adolescents with OI experience mild, yet complex pain localized across several body areas. There is little fluctuation in the pain intensity and functioning of children with OI undergoing bisphosphonate treatment.
What is Known
:
• Acute and chronic musculoskeletal pain remains a major issue in OI
.
• Pain has a negative impact on quality of life
.
What is New
:
• New and unpublished methods and findings describing the pain and quality of life of children and adolescents with OI over one intravenous bisphosphonate treatment cycle from a child
-
and parental
-
proxy perspective
.
• Children and adolescents with OI experience pain intensity that is mild, yet complex in quality and localized across several body areas
.